Patient and donor characteristics
| . | PBSC group . | BM group . |
|---|---|---|
| No. of patients | 107 | 107 |
| Recipient age | 35 (5-56) | 37 (1-55) |
| Donor age | 33 (20-53) | 36 (18-55) |
| Recipient sex (M/F) | 56/51 | 60/47 |
| Donor sex (M/F) | 72/35 | 62/44 |
| Diagnoses | ||
| AML | ||
| CR1 | 12 | 11 |
| CR2 | 8 | 11 |
| Not in remission | 16 | 13 |
| ALL | ||
| CR1 | 5 | 7 |
| CR2-3 | 6 | 4 |
| Not in remission | 5 | 6 |
| CML | ||
| CP1 | 39 | 42 |
| CP2 | 4 | 1 |
| Acc phase | 6 | 6 |
| Blast crisis | 2 | 3 |
| Lymphoma | 1 | 0 |
| Myelodysplastic syndrome | 2 | 2 |
| Aspartylglycosaminurea | 1 | 1 |
| Recipient CMV serology (−/+) | 43/64 | 47/59 |
| Donor CMV serology (−/+) | 61/46 | 58/48 |
| Follow-up, mo, median (range) | 11.1 (1.9-49)* | 20.8 (2.8-66) |
| . | PBSC group . | BM group . |
|---|---|---|
| No. of patients | 107 | 107 |
| Recipient age | 35 (5-56) | 37 (1-55) |
| Donor age | 33 (20-53) | 36 (18-55) |
| Recipient sex (M/F) | 56/51 | 60/47 |
| Donor sex (M/F) | 72/35 | 62/44 |
| Diagnoses | ||
| AML | ||
| CR1 | 12 | 11 |
| CR2 | 8 | 11 |
| Not in remission | 16 | 13 |
| ALL | ||
| CR1 | 5 | 7 |
| CR2-3 | 6 | 4 |
| Not in remission | 5 | 6 |
| CML | ||
| CP1 | 39 | 42 |
| CP2 | 4 | 1 |
| Acc phase | 6 | 6 |
| Blast crisis | 2 | 3 |
| Lymphoma | 1 | 0 |
| Myelodysplastic syndrome | 2 | 2 |
| Aspartylglycosaminurea | 1 | 1 |
| Recipient CMV serology (−/+) | 43/64 | 47/59 |
| Donor CMV serology (−/+) | 61/46 | 58/48 |
| Follow-up, mo, median (range) | 11.1 (1.9-49)* | 20.8 (2.8-66) |
AML indicates acute myeloid leukemia; ALL, acute lymphocytic leukemia; Acc phase, accelerated phase.
P < .001.